FindTrial
Sign In

Clinical study of the application of Light Therapy in the treatment of Taste Disorders in post-COVID-19 patients

Clinical study of the application of Photobiomodulation in treatment of Dysgeusia in post-COVID-19 patients

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
REBEC
Registry ID
RBR-2mfbkkk
Enrollment
Unknown
Registered
2022-03-07
Start date
2022-03-20
Completion date
Unknown
Last updated
2025-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dysgeusia

Interventions

The intervention of this study will consist of the application of a low-intensity laser protocol and Intravascular Laser Irradiation of Blood (ILIB) in 90 patients in our sample, associated with olfac
E02.594.540

Sponsors

Pontifícia Universidade Católica de Campinas
Lead Sponsor
Pontifícia Universidade Católica de Campinas
Collaborator

Eligibility

Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: Tested positive for coronavirus (COVID-19) after the Reverse Transcriptase Reaction followed by Polymerase Chain Reaction (RT-PCR) examination and who complained of symptoms of dysgeusia; Patients aged 18 years or older; Patients who are not in the disease transmission phase (fifteen days after the onset of symptoms); Patients who accept to be part of the research by signing the Free and Informed Consent Term; Patients who underwent gustatory dysfunction assessment tests and dysgeusia was confirmed

Exclusion criteria

Exclusion criteria: Patients who tested negative for coronavirus (COVID-19) after the Reverse Transcriptase Reaction followed by Polymerase Chain Reaction (RT-PCR) test; No complaints of dysgeusia symptoms; Under 18 years old; Pregnant and/or lactating patients; Patients who do not accept to participate in the research or who do not sign the Free and Informed Consent Form

Design outcomes

Secondary

MeasureTime frame
It is expected that, with the application of Laser Irradiation of Blood (ILIB) associated with photobiomodulation, there will be a faster reversal of dysgeusia symptoms in the group that will be applied laser therapy compared to the group that will only be simulated with light therapy. The time of dysgeusia reversal in both groups will also be observed.—

Primary

MeasureTime frame
It is expected that, with the application of a non-invasive therapy with low intensity laser, which will consist of the systemic photoactivation of the carotid artery and the photobiomodulation of the taste buds and salivary glands, it will present results of reducing the manifestation of dysgeusia as a sequel of the coronavirus (COVID-19).—

Countries

Brazil

Contacts

Public ContactLetícia Parreira

Pontifícia Universidade Católica de Campinas

lfsparreira@icloud.com+55 (19) 997283057

Outcome results

None listed

Source: REBEC (via WHO ICTRP) · Data processed: Feb 6, 2026